<SEC-DOCUMENT>0001193125-25-186417.txt : 20250822
<SEC-HEADER>0001193125-25-186417.hdr.sgml : 20250822
<ACCEPTANCE-DATETIME>20250822160532
ACCESSION NUMBER:		0001193125-25-186417
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250822
DATE AS OF CHANGE:		20250822

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MiNK Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268143
		FILM NUMBER:		251246277

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		212-994-8250

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgenTus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210112
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d891898d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>As Filed Pursuant to Rule 424(b)(5) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-268143</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To Prospectus dated
November&nbsp;8, 2022 and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospectus Supplement dated July&nbsp;15, 2025) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g891898g0822191123725.jpg" ALT="LOGO" STYLE="width:2.61111in;height:0.827083in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Up to $36,585,515 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement (this &#8220;Current Prospectus Supplement&#8221;) supplements the prospectus dated November&nbsp;8, 2022 (the &#8220;Base
Prospectus&#8221;) and the prospectus supplement dated July&nbsp;15, 2025 (the &#8220;Initial Prospectus Supplement&#8221;, and together with the Base Prospectus, the &#8220;ATM Prospectus&#8221;), relating to the offer and sale of shares of our
common stock from time to time pursuant to the terms of the At Market Issuance Sales Agreement, dated July&nbsp;15, 2025 (the &#8220;Agreement&#8221;), with B. Riley Securities, Inc. as sales agent. This Current Prospectus Supplement should be read
in conjunction with the ATM Prospectus. This Current Prospectus Supplement is qualified by reference to the ATM Prospectus, except to the extent that the information presented herein supersedes the information contained in the ATM Prospectus. This
Current Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus and any future amendments or supplements thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date hereof, the aggregate market value of our outstanding common stock held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> calculated
in accordance with General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as amended (our &#8220;public float&#8221;), was approximately $98.8&nbsp;million, based on 1,539,804 outstanding
shares of common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of August&nbsp;12, 2025, at a price of $64.17 per share as of July&nbsp;11, 2025, which was the highest closing sale price of our common stock on the Nasdaq
Capital Market within 60 days of the filing date of this Current Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are filing this Current Prospectus Supplement to amend the ATM
Prospectus to update our public float and indicate that, since our public float is above $75.0&nbsp;million, we are no longer subject to the sales limitations of General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> with
respect to the registration statement of which the ATM Prospectus, as amended hereby, forms a part. If we become subject to the limitations of such General Instruction I.B.6 in the future, we will file another supplement to the ATM Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through August&nbsp;21, 2025, we have offered and sold 478,462 shares of common stock for gross proceeds of $13,414,485 pursuant to the Agreement.
Accordingly, because we are no longer subject to the sales limitations of such General Instruction I.B.6, we may offer and sell up to an additional $36,585,515 of shares of common stock pursuant to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;INKT&#8221;. On August&nbsp;21, 2025, the last reported sale price of our
common stock on the Nasdaq Capital Market was $14.95 per share. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>You should read carefully and consider the &#8220;Risk Factors&#8221; referenced on page <FONT STYLE="white-space:nowrap">S-5</FONT> of the ATM Prospectus
and the risk factors described in other documents incorporated by reference herein. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Sole Sales Agent </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>B. Riley Securities </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is August&nbsp;22, 2025. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g891898g0822191123725.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g891898g0822191123725.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. /<# 2(  A$! Q$!_\0
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M Z/0?#<7B?X0VMDP G4,T+X^ZP->:>&]:O/!7BGS)590C^5<Q>JYKVKX7_\
M(@Z?]&_G7(?%[PEG;X@LXO\ 9N0H_)J /6;.[AOK.*Z@</%*H96'<&O+OC=_
MQX:5_P!='_D*I_"/Q>4D_P"$>O9/E/S6S,>GJM7?C=_QX:5_UT?^0H N?!7_
M )%B\_Z^C_(5O?$S_DG^J?[J_P#H0K ^"O\ R+%Y_P!?1_D*W_B9_P D_P!4
M_P!U?_0A0!Y=\);^VTS6]2O+R58H(K,EF8_[0K/\:^-;SQAJ*VUNKI8J^V&
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MM5DU#3+I+9Y3F2-U^4GU%>CV]W!=Q>9!(LB>JFG+/&\CQJX+IC<O<4!9G+^
M/"MSX3TB>SNIXYGDF,@9!QC K5\4:*?$/AZZTM9O),X WXSC!!_I6G%/'-N,
M;AMK%3CL1VJE/K-K!JD5@\B"1U+9+#CVI70U%MV2.3\$?#Q_"&JSWK7XN/-B
M\O:$QCG.:[ZJUVSBUD,<JQ-CAW&0M31D^6N3DXY([TR;:#Z\N^(_PYEUB?\
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IA9X#M<>AQ[^U%;:>'M-20-Y!8+]U'<LB_12<45#C(Z(UZ:6M_EH?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
